Drug Profile
Research programme: SB 9000 - F-star Therapeutics
Alternative Names: MBI 1313; MX 1313; ORI 7246; SB 9000; SB 9001; SB 9002 1Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator MIGENIX
- Developer Spring Bank Pharmaceuticals
- Class Nucleotides; Small molecules
- Mechanism of Action Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 29 May 2013 Discontinued - Preclinical for Hepatitis B in USA (PO)